A male-specific increase in the HLA-DRB4 (DR53) frequency in high-risk and relapsed childhood ALL.

Abstract	Previous studies reported significant HLA-DR associations with various leukemias one of which is with HLA-DRB4 (DR53) family in male patients with childhood ALL. We have HLA-DR-typed 212 high-risk or relapsed patients with childhood (n=114) and adult (n=98) ALL and a total of 250 healthy controls (118 children, 132 adult) by PCR-SSP analysis. The members of the HLA-DRB3 (DR52) family were underrepresented in patients most significantly for HLA-DRB112 (P=0.0007) and HLA-DRB113 (P=0.0001). In childhood ALL, the protective effect of DRB3 was evident in homozygous form (P=0.001). The DRB4 marker frequency was increased in males with childhood ALL (67.4%) compared to age- and sex-matched controls (42.1%, P=0.003) and female patients (35.7%, P=0.004). Besides being a general marker for increased susceptibility to childhood ALL in males, HLA-DRB4 is over-represented in high-risk patients. These results further suggest that the HLA system is one of the components of genetic susceptibility to leukemia but mainly in childhood and in boys only.
Authors	M Tevfik Dorak, Fatma S Oguz, Nevin Yalman, A Sarper Diler, Sevgi Kalayoglu, Sema Anak, Deniz Sargin, Mahmut Carin
Journal	Leukemia research (Leuk Res) Vol. 26 Issue 7 Pg. 651-6 (Jul 2002) ISSN: 0145-2126 [Print] England
PMID	12008082 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antigens, Neoplasm HLA-DR Antigens HLA-DR53 HLA-DRB3 Chains HLA-DRB4 Chains
Topics	Adult Antigens, Neoplasm (analysis, genetics) Child Female Gene Frequency Genes, MHC Class II Genetic Predisposition to Disease Genotype HLA-DR Antigens (analysis, genetics) HLA-DRB3 Chains HLA-DRB4 Chains Humans Immunity, Innate (genetics) Male Precursor Cell Lymphoblastic Leukemia-Lymphoma (epidemiology, genetics) Recurrence Retrospective Studies Risk Sex Characteristics Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!